



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 03 July 2023 (#24)

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

**To prepare an application can take 4-18 months, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

**Before starting your application, attend the 1) Generic Grant Writing Workshop and then the 2) NIH Grant Writing Workshop.**

## Important Notices

**NOT-OD-23-155 Findings of Research Misconduct:** Findings of research misconduct have been made against a Postdoctoral Fellow, Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University (OSU), and Postdoctoral Fellow, Department of Oncology, Johns Hopkins University (JHU). ORI found that Respondent engaged in research misconduct by intentionally and knowingly falsifying and/or fabricating data, methods, results, and conclusions

**Successful Sample Applications Demonstrate Good Grantsmanship.** One way to hone your grantsmanship skills is to examine well-written examples of successful grant applications. When you do so, remember that your application must also follow the latest official NIH [How To Apply](#) SF 424 instructions.

**NOT-MH-23-355 Notice of Pre-Application and Technical Assistance Webinar for RFA-MH-23-300 Developing Measures to Advance Access and Quality in Global Mental Health Services (R34 Clinical Trial Not Allowed)** The National Institute of Mental Health (NIMH) will host a pre-application and technical assistance webinar on July 17, 2023, 9:00 a.m. - 10:30 a.m. Eastern Time (ET) to provide information and respond to questions from prospective applicants who plan to submit applications. The webinar will be hosted through ZoomGov Meeting. <https://nih.zoomgov.com/j/1617431683?pwd=VUptVyttSnBHMIp3N1JTVmxCcEI5UT09>

**NOT-MH-23-360 Notice of Technical Assistance Webinar for RFA-MH-24-120, "Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)".** This phased NOFO aims to create a pipeline to accelerate the development and early validation of predictive tools and biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. A technical assistance webinar will be held for prospective applicants on July 11, 2023, 2:00 to 3:00 p.m. Eastern Time (ET). The webinar will be hosted through Zoom. Join [ZoomGov Meeting](#)

**NOT-LM-23-003 Notice of Intent to Publish a Funding Opportunity Announcement for Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional).** The National Library of Medicine (NLM), with other NIH Institutes and Centers (ICs), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NOFO is

expected to be published on July 28, 2023. First Estimated Application Due Date: October 05, 2023. Application budgets are generally expected to be no more than \$250,000 per year in direct costs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Potential applicants are encouraged to use this time to seek out community and potential end user engagement.

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
*Expiration Date: May 8, 2023* **Modified Key Dates** *Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **[PA-20-185](#)** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **[PA-20-184](#)** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **[PA-20-183](#)** Research Project Grant (Parent R01 Clinical Trial Required)
- **[PA-20-200](#)** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **[PA-20-195](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **[PA-20-194](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **[PA-20-196](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

**[NOT-AA-23-011](#) Secondary Analyses of Existing Alcohol Research Data.** The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research. This notice applies to due dates on or after October 05, 2023, and subsequent receipt dates through September 06, 2026. Submit applications for this initiative using one of the notices of funding opportunity (NOFO) listed in the NOSI.

**[NOT-AI-23-050](#) Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections.** This Notice of Special Interest (NOSI) encourages applications that seek to better understand Pulmonary Non-Tuberculous Mycobacteria (NTM) Infections and inform development of medical countermeasures. This notice applies to application receipt dates on or after October 5, 2023 and subsequent receipt dates through July 16, 2026. Submit applications for this initiative using one of the notices of funding opportunity (NOFO) listed in the NOSI.

## Notice of Funding Opportunity (NOFO)

### 1. Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-24-023](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to July 05, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this NOFO is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R01 grant mechanism, while the companion NOFO ([PAR-24-026](#)), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

## 2. Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-24-024](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to July 05, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This NOFO encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize *in vivo*, *in situ* or *in vitro* experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO [PAR-24-025](#)

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

## 3. Advancing Development of Diagnostics for Congenital and Adult Acquired Syphilis (R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-23-039](#)

**Type:** R21

**Application Due Date:** November 02, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this NOFO is to develop new and advance existing diagnostics for congenital and adult acquired syphilis infections by leveraging recent advances in *Treponema pallidum* basic research and broader infectious disease diagnostic innovations.

**Budget:** NIAID intends to commit \$3.2M in FY 2024 to fund 8-12 awards. Application budgets are not expected to exceed \$275,000 in direct costs for the two-year project period and should reflect the actual needs of the proposed project. No more than \$200,000 should be requested in any single year. The maximum project period is 2 years.

## 4. Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment (R21/R33 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-24-100](#)

**Type:** R21/R33

**Application Due Date:** November 22, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This NOFO encourages participatory data science and implementation science research to accelerate the implementation of more targeted and sustainable HIV interventions with the goals of (1) using data science methods to model complex systems, including social and structural determinants of health, to identify more targeted HIV prevention, treatment, and care interventions and implementation strategies; (2) using novel measurement approaches and modern statistical methods to evaluate the implementation of data-driven discoveries; (3) integrating meaningful engagement of community and implementing partners at every stage of the research. This NOFO will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support to engage interested/affected parties in the model design, development, testing, and model simulation and up to 3 years of R33 support for expanded activities for translation, implementation, evaluation, and assessment of the model. Transition to the R33 phase is not guaranteed for all grants awarded under this NOFO. Continuation from the R21 phase to the R33 phase will be determined by the NIMH based on progress achieved in the R21 phase and other factors such as program priorities and availability of funds.

**Budget:** NIMH intends to commit \$800,000 in FY 24 to fund up to 3-4 awards. In the R21 phase, applications may not exceed \$275,000 in direct costs over the two-year period. No more than \$200,000 in direct costs may be budgeted for any year. In the R33 phase, applications may not exceed \$375,000 in direct costs over the three-year period. No more than \$200,000 in direct costs may be budgeted in any given year.

## 5. Analysis of data in the COVID-19 Neuro Databank-Biobank (R03 - Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-24-025](#)

**Type:** R03

**Application Due Date:** November 08, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this NOFO is to invite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVID Project). The NeuroCOVID Project was established in 2020 to serve as a robust national resource to understand the neurological complications associated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications of COVID-19 by using this de-identified database. The data may be combined with data from other U.S. and International databases for analyses. However, collection of new primary data from those affected by COVID-19 or comparison cohorts is NOT covered by this NOFO.

**Budget:** NINDS intends to commit up to \$400,000 (total costs) in FY 2024 to fund 4-5 awards contingent upon NIH appropriations and a sufficient number of meritorious applications. Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed two years.

**Research Development and Support Division (RDSD) & Grants Management Office (GMO)**  
**Faculty of Medicine and Health Sciences**  
009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

**Division for Research Development (DRD)**  
**Stellenbosch Campus**  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105